Publications
Search our bibliography using the filters on the right-hand side.
Displaying 1 through 50 of 51 publications.
Skip to main content
Riemer J, Campbell K, Arthurs E, Knight C. Cost-effectiveness of belimumab for the treatment of adults with active lupus nephritis in Canada. Presented at the ISPOR 2025; May 15, 2025. Montréal, Canada.
Herring WL, Coon C, Lenderking W, Whittington M. Rethinking clinical meaningfulness and value assessment in the context of chronic progressive diseases. Presented at the ISPOR 2025; May 15, 2025. Montréal, Canada.
Cook C, Carrico J, Talbird S, Gountas I, Skroumpelos A, Boutselakou E, Trimis G, Sabale U, Bencina G. Public health and economic impact of pediatric immunization program in Greece. Presented at the 42nd Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID) 2024; May 24, 2024. Copenhagen, Denmark.
Ghaswalla P, Carrico J, Hicks KA. The annual economic burden of respiratory syncytial virus in adults in the United States. Presented at the 2024 Biomedical Advanced Research and Development Authority George Risi Memorial Journal Club; January 22, 2024.
Barbieri M, Senese F, Mellott CE, Boccalini S, Carrico J, Bechini A, Talbird SE, Chen Y-H, Bencina G. Public health impact and return on investment of the pediatric national immunization program in Italy. Presented at the Italian Society of Hygiene, Preventive Medicine, and Public Health Conference; October 12, 2023. Cernobbio, Italy.
Bonastre J, Negrier S, Colrat F, Chamielec C, Teitsson S, Knight C, Ni L, Chevalier J, Gaudin AF, Roupret M, Branchoux S. Impact of method for modelling distant recurrence (DR) on cost-effectiveness (CE) of nivolumab (NIVO) as an adjuvant treatment of muscle-invasive urothelial carcinoma (MIUC) patients with high risk of recurrence in France. Presented at the ISPOR Europe 2022; November 6, 2022. Vienna, Austria.
La E, Poston S, Curran D, Lorenc S, Salem AE, Carrico J, Hicks KA, Anderson S, Carpenter CF. Cost-effectiveness analysis of recombinant zoster vaccine for vaccinating immunocompromised adults against Herpes Zoster in the United States. Presented at the ACIP Herpes Zoster Working Group; April 2021. Atlanta, GA.
Herring W, Benham-Hermetz S, Gustavsson A, Hayek Y. Assessing the value of delayed progression in early Alzheimer's disease: what are the critical issues? Presented at the HTAi 2020 Virtual Annual Meeting; October 13, 2020.
Herring W, Rosen B. Economic model for ResVax for maternal vaccination against infant respiratory syncytial virus disease in the United States. Presented at the 2019 Respiratory Syncytial Virus Consortium in Europe; June 2019. Utrecht, The Netherlands.
Brogan AJ, Talbird SE, Davis AE, La EM, Miao Z, Lewis S. Long-term health benefit of ibalizumab in the treatment of adults with multidrug-resistant HIV-1 infection. Presented at the 2018 ISPOR 23rd Annual International Meeting; May 23, 2018. Baltimore, MD.
Wasserman M, Rejas J, Mendez C, Wilson M, McDade C, Moffatt M, Farkouh R. Estimating clinical and economic impact of switching from the 13-valent (PCV13) to the 10-valent (PCV10) Pneumococcal Conjugate Vaccine in Spain. Presented at the 35th Annual Meeting of the European Society for Paediatric Infectious Diseases; May 24, 2017. Madrid, Spain.
Curran D, Van Oorschot D, Buck PO, Patterson BJ, Lee BY, Yawn BP, Hicks KA, Carrico J. Cost-effectiveness analysis of Shingrix for vaccinating US adults against herpes zoster. Presented at the ACIP Herpes Zoster Working Group; May 2017. Atlanta, GA.
Yaylali E, Farnham P, Sansom S, Hicks KA, Honeycutt A, Tucker E. Using the HOPE model for evaluating HIV interventions in the US. Presented at the 2016 INFORMS Annual Meeting; November 13, 2016. Nashville, TN.
Jacobson E, Hicks KA, Yaylali E, Chen YH, Sansom S. Effects of reaching national HIV/AIDS strategy viral load suppression goal on HIV incidence, by race and ethnicity, in the United States. Presented at the 38th Annual North American Meeting of the Society for Medical Decision Making; October 24, 2016. Vancouver, Canada.
Hicks KA, Bowers LD. A model for developing athlete testing strategies based on the costs and benefits of doping. Presented at the 14th Annual USADA Symposium on Anti-Doping Science; October 4, 2015. Leesburg, VA.
Herring WL, Grant TJ, Mladsi DM. A mathematical model to estimate the health benefits and costs of diabetic retinopathy screening programs. Presented at the 2015 Institute for Operations Research and Management Science Computing Conference; January 12, 2015. Richmond, VA.
Fehnel SE. Choice of recall period in patient-reported outcome measurement. Presented at the 4th Annual Patient-Reported Outcome Consortium Workshop; April 1, 2013.
Wolowacz SE, Pearson IV, Roskell NS, Shannon PR, Chubb B, Gundgaard J. Development and validation of a cost-utility model for Type 1 diabetes mellitus. Presented at the Mount Hood Six Challenge; June 7, 2012.
Brogan AJ, Talbird SE, Thompson J, Miller JD, George S, Hvidsten K. Cost-effectiveness of first-line versus second-line telaprevir combination treatment in the management of chronic hepatitis C virus infection for treatment-naïve patients with IL28B genotype CC. Presented at the 2012 Digestive Disease Week; May 2012.
Earnshaw SR, Chirila C, McDade CL, Black L, Andriole GL. Cost-effectiveness of dutasteride as a chemoprevention in prostate cancer: rEDUCE within-trial analysis. Presented at the 2011 ISPOR 16th Annual International Meeting; May 2011.
Mladsi DM, Redekop K, Goettsch A, Earnshaw SR. Challenges and insights in establishing and communicating the economic value of companion diagnostics. Presented at the 2010 ISPOR 13th Annual European Congress; November 2010. Prague, Czech Republic.
Zarkin GA, Cowell AJ, Dunlap LJ, Hicks KA, Keyes VS, Mills MJ. Benefits and costs of alternative substance abuse treatment programs for individuals in state prisons: results from a lifetime simulation model. Presented at the American Society of Criminology Annual Meeting; November 2009. Previously presented at the Addiction Health Services Research Annual conference.
Zarkin GA, Cowell AJ, Hicks KA, Dunlap LJ, Belenko S, Mills MJ. Benefits and costs of alternative substance abuse treatment programs for individuals in state prisons: results from a lifetime simulation model. Presented at the Addiction Health Services Research Annual conference; October 2009.
Mladsi D, de Cambra S, Gilabert-Perramon A, Faulkner EC. Orphan drug funding: a model for personalized medicine? Presented at the 2009 ISPOR 12th Annual European Congress; October 2009. Paris, France.
Hoerger TJ, Zhang P, Segel JE, Gregg EW, Narayan K, Hicks KA. Improvements in risk factor control among persons with diabetes in the United States: evidence and implications for remaining life expectancy. Presented at the 7th World Conference on Health Economics; July 2009. Previously presented at the American Diabetes Association 69th Scientific Sessions.
Hoerger TJ, Zhang P, Segel JE, Gregg E, Narayan K, Hicks KA. Improvements in risk factor control among persons with diabetes in the United States: evidence and implications for remaining life expectancy. Presented at the American Diabetes Association 69th Scientific Sessions; June 2009.
Ross MT, DeAngelo B, Beach RH, Gallaher MP, Pattanayak SK, Poulos C, Waldhoff S. Representing the impacts of climate change in a US economic model. Presented at the Climate Change: Global Risks, Challenges, & Decisions; March 2009. Copenhagen, Denmark.
Zarkin GA, Cowell AJ, Dunlap LJ, Hicks KA, Keyes VS, Mills MJ. Simulating the costs and benefits of prison-based substance abuse treatment. Presented at the Addiction Health Services Research; October 2008.
Hicks KA, Uzunangelov VJ, Lasry A, Sansom S. Allocating CDC's HIV prevention funds. Presented at the 2008 INFORMS Annual Meeting; October 2008.
Hicks KA, Richter A. Impact of uncertainty in hiv resource allocation. Presented at the 2008 INFORMS Annual Meeting; October 2008.
Richter A, Hicks KA. Costs of equity in hiv prevention. Presented at the CDC NCHSTP Seminar; February 2008.
Sansom S, Lasry A, Hicks KA. The optimal allocation of HIV prevention dollars. Presented at the Centers for Disease Control and Prevention Division of HIV/AIDS Prevention Project Officers' Meeting; December 2006.
Hicks KA. Making use of cost-effectiveness analysis in the community planning process: methods and tools. Presented at the Centers for Disease Control and Prevention Division of HIV/AIDS Prevention Project Officers' Meeting; December 2006.
Mladsi DM. Developing health economic models for assessing cost-effectiveness and product value. Presented at the 2006 Health Economics Conference; April 28, 2006. London, UK.
Rein DB, Hicks KA, Wirth KE, Hoerger TJ. Economics of hepatitis A immunization. Presented at the U.S. Advisory Committee on Immunization Practices; June 2005. Atlanta, GA.
Rein DB, Hicks KA, Wirth KE, Hoerger TJ. Update: economics of hepatitis A virus immunization. Presented at the ACIP Hepatitis Working Group; June 2005.
Rein DB, Hicks KA, Wirth KE, Hoerger TJ. Results of RTI's cost-effectiveness evaluation of childhood hepatitis A vaccination strategies. Presented at the U.S. Advisory Committee on Immunization Practices (ACIP); June 2005. Atlanta, GA.
Lewis SA. A practical walkthrough of an epro design kickoff. Benefits and challenges with epro: outcomes and endpoints as we emerge from the long age of paper methods. Presented at the Drug Information Association conference workshop; 2005.
Finkelstein EA, Hicks KA. Obesity cost calculator for employers. Presented at the 2004 National Business Group on Health Founding Board Meeting; February 2004.
Sorensen SW, Hicks KA, Wirth K, Hoerger TJ, Narayan K, Saaddine J. Optimal allocation of resources based on the diabetes report card for quality care. Presented at the Institute for Operations Research and the Management Sciences Annual Meeting; October 2003.
Zarkin GA, Dunlap LJ, Hicks KA, Mamo D, Mobley LR. Benefits and costs of methadone treatment: results from a lifetime simulation model. Presented at the International Health Economics Association Meeting; June 15, 2003.
Fehnel SE, McLeod LD, Williams VS. Combining qualitative and quantitative techniques in the development of patient-reported outcome measures. Presented at the Eighth Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research; May 2003.
Hicks KA, Honeycutt A, Earnshaw SR, Richter A. Models for the efficient allocation of HIV prevention resources. Presented at the Community Planning Leadership Summit for HIV Prevention; March 2003.
Poulos C, Smith VK. A preliminary analysis of economic factors affecting childhood asthma. Presented at the Add Health Users Workshop. National Institutes of Health; August 2001. Bethesda, MD.
Hauber AB, Bala MV, Fehnel SE. Conducting cost-benefit and cost-utility analysis: a conjoint analysis approach. Presented at the Annual Meetings of the International Society of Pharmacoeconomics and Outcomes Research; May 2001.
Neighbors DM, Candrilli SD. Concomitant medication costing using clinical trial data: a case study. Presented at the 2000 ISPOR 5th Annual International Meeting; May 2000. Arlington, VA.
Neighbors DM. Potential for bias when using clinical trial adverse event rates to estimate toxicity costs. Presented at the 1999 ISPOR 2nd Annual European Congress; November 1999. Edinburgh, Scotland.
Neighbors DM, Downs KE. Medical resource use data collection in clinical trials. Presented at the DIA Meeting Session Economic Assessment in Clinical Trials: Design and Analysis; November 1999. Orlando, FL.
Neighbors D. Clinical benefit endpoints in trials for the treatment of non-small cell lung cancer and hormone-refractory prostate cancer. Presented at the Investigator Meeting; 1998. San Diego, CA.
Neighbors D. Pharmacoeconomic endpoints in FUMA3007: a randomized, open-label study comparing a 28-day oral regimen of 5-fluorouracil plus 776c85 to intravenous gemcitabine for the first-line treatment of patients with unresectable advanced adenocarcinoma of the pancreas. Presented at the Investigator Meeting; 1997. Atlanta, GA.